Ranimustine

This classification denotes a nitrosourea compound with the molecular formula C10H18ClN3O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RYH2T97J77, chemically known as glucopyranoside, methyl-6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-, alpha-d- but more generally known as ranimustine, which bears US NIH Compound Identifier 71741. European Medicines Agency schedules Ranimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10256MIG. The term RANIMUSTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules ranimustine in its Anatomical Therapeutic Chemical (ATC) Classification. RANIMUSTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule ranimustine under HS 29329970 and SITC 51569. As of Q4 2014, RANIMUSTINE remains US FDA's Preferred Term for this commodity. Ranimustine bears US NLM identifiers UMLS ID C0243666 and NCI Concept Code C1515. SMILES: COC1C(C(C(C(O1)CNC(=O)N(CCCL)N=O)O)O)O.